We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.
- Authors
Xu, Yan; Deng, Shuhui; Mao, Xuehan; An, Gang; Li, Zengjun; Wang, Yafei; Fulciniti, Mariateresa; Ho, Matthew; Lin, Jianhong; Sui, Weiwei; Liu, Wei; Zou, Dehui; Yi, Shuhua; Huang, Wenyang; Liu, Hong; Lv, Rui; Li, Jian; Wang, Tingyu; Du, Chenxing; Munshi, Nikhil C.
- Abstract
<bold>Background: </bold>Peripheral neuropathy (PN) is an important toxicity that limits the use of bortezomib (Btz). Attempts to reduce PN have included its subcutaneous (SC) administration.<bold>Patients and Methods: </bold>We retrospectively analyzed 307 patients with newly diagnosed multiple myeloma from a single Chinese center, receiving Btz-based regimens administered either via SC injection (SC group, n = 167) or intravenous (IV) infusion (IV group, n = 140). The efficacy and safety of Btz administration via SC and IV were then compared.<bold>Results: </bold>Most baseline characteristics were similar between these 2 groups. A lower frequency of adverse events, especially grade ≥ 3 PN (P = .002), was observed in the SC group compared with the IV group. The estimated median Btz dosage when PN developed was higher (20.8 mg/m2 vs. 15.6 mg/m2), and fewer patients reduced or discontinued Btz owing to adverse events in the SC group compared with the IV group. The overall response rate (≥ partial response [PR]) was comparable (94.8% vs. 96.2%). However, patients in the IV group required fewer cycles to achieve PR, whereas a larger proportion of patients in the IV group achieved ≥ very good PR. After a median follow-up of 23 months (range, 1-84 months), no significant difference in median progression-free survival (not arrived vs. 33.0 ± 2.735 months) and overall survival (not arrived vs. 56.0 months) was noted.<bold>Conclusion: </bold>SC Btz is associated with better tolerance; however, IV administration achieves a faster and deeper response in Chinese patients with newly-diagnosed multiple myeloma.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2018, Vol 18, Issue 6, p422
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2018.03.006